Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial

SIGNAL is a multicenter, randomized, double-blind, placebo-controlled phase 2 study (no. NCT02481674) established to evaluate pepinemab, a semaphorin 4D (SEMA4D)-blocking antibody, for treatment of Huntington’s disease (HD). The trial enrolled a total of 265 HD gene expansion carriers with either ea...

Descripción completa

Detalles Bibliográficos
Autores principales: Feigin, Andrew, Evans, Elizabeth E., Fisher, Terrence L., Leonard, John E., Smith, Ernest S., Reader, Alisha, Mishra, Vikas, Manber, Richard, Walters, Kimberly A., Kowarski, Lisa, Oakes, David, Siemers, Eric, Kieburtz, Karl D., Zauderer, Maurice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361919/
https://www.ncbi.nlm.nih.gov/pubmed/35941373
http://dx.doi.org/10.1038/s41591-022-01919-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361919/
https://www.ncbi.nlm.nih.gov/pubmed/35941373
http://dx.doi.org/10.1038/s41591-022-01919-8

Ejemplares similares